GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.
INmune Bio: Alzheimer’s Trial Results and Stock Shock
The recent news surrounding INmune Bio has sent ripples through the biotechnology investment world, causing the company's stock to plummet by over 50%. This dramatic drop wasn't due to a scandal or financial mismanagement, but rather the outcome of a clinical trial for their Alzheimer's disease drug, XPro.
Optimizing FDA Diversity Action Plan Compliance and Alzheimer’s Clinical Trial Matching Through Agentic AI
Discover how Glassbury AI leverages agentic NLP, SMART on FHIR protocols, and trust-centric community frameworks to solve Alzheimer's trial enrollment bottlenecks, de-risk asset beta, and automate FDA Diversity Action Plan (DAP) compliance under FDORA.
The Role of AI in Therapeutic Drug Research and Development: Benefits and Challenges
Artificial intelligence (AI) has emerged as a transformative technology across various sectors, and its potential impact on therapeutic drug research and development is significant. By leveraging AI algorithms and machine learning, researchers can potentially accelerate the drug discovery process, identify promising drug candidates, and optimize treatment strategies. However, the integration of AI
Combating Alzheimer's: Current Treatments and Promising Pipeline Drugs
Alzheimer's disease is a devastating neurodegenerative disorder that affects millions worldwide. As the global population ages, the prevalence of Alzheimer's and related dementias is expected to rise significantly.
The Regulatory Shift: Why Diversity Is Now a Technical Requirement
Discover how Glassbury AI’s agentic NLP platform, SYCQ 1.0, solves the FDA Diversity Action Plan (DAP) mandate and accelerates Phase III Alzheimer’s clinical trial matching.